Developing tests for early detection of aggressive prostate cancer
Biomarker Reference Laboratory
This study is working on new tests to help find aggressive prostate cancer early, so that patients can get personalized treatment based on their unique genetic markers, making it easier to catch and manage the disease effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10891590 on NIH RePORTER |
What this research studies
This research focuses on creating and validating clinical-grade tests to detect aggressive prostate cancer at an early stage. The project involves a collaboration between the University of Michigan and Vanderbilt University Medical Center, utilizing advanced biomarkers to improve diagnostic accuracy. Patients will benefit from tests that provide personalized risk assessments based on specific genetic markers, which can guide treatment decisions. The research aims to enhance the early detection of potentially lethal cancers, allowing for timely and effective interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research include African American men who are at higher risk for aggressive prostate cancer.
Not a fit: Patients with non-aggressive prostate cancer or those who do not fall within the targeted demographic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of aggressive prostate cancer, improving treatment outcomes for patients.
How similar studies have performed: Previous research has successfully identified biomarkers for prostate cancer detection, indicating a promising foundation for this novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Tosoian, Jeffrey John — University of Michigan at Ann Arbor
- Study coordinator: Tosoian, Jeffrey John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.